BR112017000519A2 - "composição imunogênica, e, método para proteger um mamífero contra uma infecção meningocócica" - Google Patents

"composição imunogênica, e, método para proteger um mamífero contra uma infecção meningocócica"

Info

Publication number
BR112017000519A2
BR112017000519A2 BR112017000519A BR112017000519A BR112017000519A2 BR 112017000519 A2 BR112017000519 A2 BR 112017000519A2 BR 112017000519 A BR112017000519 A BR 112017000519A BR 112017000519 A BR112017000519 A BR 112017000519A BR 112017000519 A2 BR112017000519 A2 BR 112017000519A2
Authority
BR
Brazil
Prior art keywords
protecting
immunogenic composition
mammal against
against meningococcal
meningococcal infection
Prior art date
Application number
BR112017000519A
Other languages
English (en)
Portuguese (pt)
Inventor
BIOLCHI Alessia
Brunelli Brunella
Monica Giuliani Marzia
Masignani Vega
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of BR112017000519A2 publication Critical patent/BR112017000519A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/116—Polyvalent bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)
BR112017000519A 2014-07-17 2015-07-16 "composição imunogênica, e, método para proteger um mamífero contra uma infecção meningocócica" BR112017000519A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14177563 2014-07-17
PCT/EP2015/066229 WO2016008961A1 (en) 2014-07-17 2015-07-16 Meningococcus vaccines

Publications (1)

Publication Number Publication Date
BR112017000519A2 true BR112017000519A2 (pt) 2017-11-21

Family

ID=51178811

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017000519A BR112017000519A2 (pt) 2014-07-17 2015-07-16 "composição imunogênica, e, método para proteger um mamífero contra uma infecção meningocócica"

Country Status (15)

Country Link
US (3) US11707513B2 (https=)
EP (1) EP3169358A1 (https=)
JP (2) JP6687597B2 (https=)
KR (2) KR20230012100A (https=)
CN (2) CN106659776A (https=)
AR (2) AR101225A1 (https=)
AU (2) AU2015289193A1 (https=)
BE (1) BE1022878B1 (https=)
BR (1) BR112017000519A2 (https=)
CA (1) CA2954729C (https=)
EA (1) EA038940B1 (https=)
IL (1) IL249823B (https=)
MX (1) MX2017000775A (https=)
SG (2) SG10201900041VA (https=)
WO (1) WO2016008961A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160127104A (ko) 2014-02-28 2016-11-02 글락소스미스클라인 바이오로지칼즈 에스.에이. 변형된 수막구균 fhbp 폴리펩티드
JP6687597B2 (ja) 2014-07-17 2020-04-22 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 髄膜炎菌ワクチン
EP3169357B1 (en) 2014-07-17 2018-11-07 GlaxoSmithKline Biologicals S.A. Modified meningococcal fhbp polypeptides
US10975131B2 (en) * 2015-10-27 2021-04-13 University Of Massachusetts Factor H-Fc immunotheraphy
CN107151270B (zh) * 2017-03-22 2018-07-31 武汉博沃生物科技有限公司 重组ΔfHbp-NadA融合蛋白载体及其制备方法和应用
CN108939061A (zh) * 2018-08-03 2018-12-07 北京智飞绿竹生物制药有限公司 一种多组分b群脑膜炎球菌疫苗及其制备方法
EP3607967A1 (en) * 2018-08-09 2020-02-12 GlaxoSmithKline Biologicals S.A. Modified meningococcal fhbp polypeptides
US11014736B2 (en) 2019-04-18 2021-05-25 Altria Client Services Llc Sliding packs with flip top hinged lids
CN110804101A (zh) * 2019-11-08 2020-02-18 苏州微超生物科技有限公司 B群脑膜炎球菌相关融合蛋白、疫苗及其制备方法与应用
MX2022006299A (es) * 2019-11-25 2023-01-19 Univ Griffith Proteína inmunogénica contra una infección gonocócica.
GB202115151D0 (en) 2021-10-21 2021-12-08 Glaxosmithkline Biologicals Sa Methods
CN119792505A (zh) * 2023-10-10 2025-04-11 康希诺生物股份公司 一种抗脑膜炎球菌的免疫组合物及其用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6747137B1 (en) 1998-02-13 2004-06-08 Genome Therapeutics Corporation Nucleic acid sequences relating to Candida albicans for diagnostics and therapeutics
US6551795B1 (en) 1998-02-18 2003-04-22 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics
PT2289545T (pt) * 2000-01-17 2016-09-06 Glaxosmithkline Biologicals Sa Vacina de omv suplementada contra meningococos
GB0227346D0 (en) * 2002-11-22 2002-12-31 Chiron Spa 741
GB0419408D0 (en) * 2004-09-01 2004-10-06 Chiron Srl 741 chimeric polypeptides
GB0419627D0 (en) * 2004-09-03 2004-10-06 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
GB0524066D0 (en) * 2005-11-25 2006-01-04 Chiron Srl 741 ii
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
CA2779816A1 (en) 2009-10-27 2011-05-05 Novartis Ag Modified meningococcal fhbp polypeptides
CA2792687A1 (en) 2010-03-10 2011-09-15 Glaxosmithkline Biologicals S.A. Immunogenic composition
TR201802933T4 (tr) 2010-03-30 2018-03-21 Childrens Hospital & Res Center At Oakland Özellikleri değiştirilmiş faktör h bağlama proteinleri (fhbp) ve bunların kullanım yöntemi.
GB201015132D0 (en) 2010-09-10 2010-10-27 Univ Bristol Vaccine composition
GB201120634D0 (en) 2011-11-30 2012-01-11 Univ Sheffield Adjuvant polypeptide
AU2013276083B2 (en) * 2012-06-14 2018-04-05 Institut Pasteur Vaccines for serogroup X meningococcus
GB201215005D0 (en) 2012-08-23 2012-10-10 Isis Innovation Stabilised meningitis vaccine
KR20160127104A (ko) 2014-02-28 2016-11-02 글락소스미스클라인 바이오로지칼즈 에스.에이. 변형된 수막구균 fhbp 폴리펩티드
EP2916512B1 (en) 2014-03-07 2016-08-24 Mitsubishi Electric R&D Centre Europe B.V. Method for classifying a TCP connection carrying HTTP traffic as a trusted or an untrusted TCP connection
JP6687597B2 (ja) 2014-07-17 2020-04-22 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 髄膜炎菌ワクチン
EP3169357B1 (en) 2014-07-17 2018-11-07 GlaxoSmithKline Biologicals S.A. Modified meningococcal fhbp polypeptides
CA3103741A1 (en) 2018-06-21 2019-12-26 Basf Se 3-phenyl-benzofuran-2-one diphosphate derivatives as stabilizers

Also Published As

Publication number Publication date
US20230414736A1 (en) 2023-12-28
CA2954729A1 (en) 2016-01-21
AU2019201131A1 (en) 2019-03-07
BE1022878A1 (fr) 2016-09-30
EA038940B1 (ru) 2021-11-12
AR101225A1 (es) 2016-11-30
CA2954729C (en) 2023-08-22
CN106659776A (zh) 2017-05-10
JP2017522319A (ja) 2017-08-10
CN113827712A (zh) 2021-12-24
US20180214531A1 (en) 2018-08-02
SG10201900041VA (en) 2019-02-27
AU2019201131C1 (en) 2021-03-18
IL249823B (en) 2022-07-01
AR130778A2 (es) 2025-01-15
KR20230012100A (ko) 2023-01-25
IL249823A0 (en) 2017-03-30
WO2016008961A1 (en) 2016-01-21
US20260097107A1 (en) 2026-04-09
BE1022878B1 (fr) 2016-09-30
US12485164B2 (en) 2025-12-02
EA201692554A1 (ru) 2017-07-31
EP3169358A1 (en) 2017-05-24
JP2020117523A (ja) 2020-08-06
AU2015289193A1 (en) 2017-02-02
AU2019201131B2 (en) 2020-08-27
MX2017000775A (es) 2017-05-04
JP6687597B2 (ja) 2020-04-22
KR20170029615A (ko) 2017-03-15
US11707513B2 (en) 2023-07-25
SG11201610946YA (en) 2017-01-27
KR102626831B1 (ko) 2024-01-22
JP7074793B2 (ja) 2022-05-24

Similar Documents

Publication Publication Date Title
BR112017000519A2 (pt) "composição imunogênica, e, método para proteger um mamífero contra uma infecção meningocócica"
JOP20200011B1 (ar) مركبات وتركيبات لمعالجة حالات مرضية مرتبطة بنشاط nlrp
MX2019005465A (es) Metodo de tratamiento de un tumor inmunoterapeutico.
BR112016014410A2 (pt) terapia de combinação com vacina de neoantígeno
BR112018004620A2 (pt) moduladores da expressão de kras
BR112017006113A2 (pt) combinações sinérgicas de auristatina
AU2015296298A8 (en) Flagellin-based agents and uses including effective vaccination
BR112017005693A2 (pt) método para tratar e/ou prevenir uma doença hepática, e, composição farmacêutica.
JO3735B1 (ar) مركبات ألكين بها استبدال رباعي واستخداماتها
BR112014021104A2 (pt) métodos e composições para o tratamento da doença de huntington
BR112015027282A2 (pt) fenfluramina para uso no tratamento de síndrome de dravet
BR112012004806B8 (pt) composições imunogênicas que incluem moduladores da atividade de tlr, método para aumento da eficácia da referida composição e uso
BR112013019257A2 (pt) composição de androgênio para tratar uma condição oftálmica
BR112016006048A8 (pt) composições antimicrobianas
BR112018074990A2 (pt) composição, usos e método para reduzir neutropenia
BR112013020743A2 (pt) composições e métodos para a terapia e diagnóstico de influenza
BR112014019399A2 (pt) métodos de tratamento da fibrose
GT201500005A (es) Composiciones de vacuna para la prevencion contra la infeccion por el virus del dengue
BR112015004515A2 (pt) composição imunogênica
BR112013010136A2 (pt) vacina, composição terapêutica e métodos para o tratamento ou inibição de gliblastoma
BR112017026535A2 (pt) composto de fórmula estrutural i, enantiômero isolado, composição farmacêutica, método para inibir atividade do transportador de monocarboxilato mct4, método para inibir seletivamente atividade do transportador de monocarboxilato mct4, método para tratar um distúrbio mediado por transportador de monocarboxilato mct4 e uso de um composto
BR112014000542A2 (pt) composições de peroxidase eosinofílica e métodos de uso das mesmas
BR112017004197A2 (pt) composições de vacina contra doenças do vírus da dengue
BR112017023448A2 (pt) composições anti-fitopatogênicas
BR112015017903A2 (pt) vacina de subunidade de mycobacterium avium subsp. paratuberculosis única ou de múltiplos estágios

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements